We are live on ! Find out more
ONCT

Oncternal Therapeutics, Inc. Common Stock
ONCT

Delisted

ONCT was delisted on the 2nd of December, 2024.

Back to rankings

41 hedge funds and large institutions have $12.2M invested in Oncternal Therapeutics, Inc. Common Stock in 2016 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 4 increasing their positions, 10 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

350% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 2

45% more capital invested

Capital invested by funds: $8.41M → $12.2M (+$3.75M)

21% more funds holding

Funds holding: 34 → 41 (+7)

60% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 10

Holders
41
Holders Change
+7
Holders Change %
+20.59%
% of All Funds
1.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
4
Reduced
10
Closed
2
Calls
$5K
Puts
–
Net Calls
+$5K
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Deutsche Bank
Deutsche Bank
Germany
+$45.4K
2
Renaissance Technologies
Renaissance Technologies
New York
+$45.4K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$34.9K
4
Citadel Advisors
Citadel Advisors
Florida
+$34K
5
EWA
Exencial Wealth Advisors
Oklahoma
+$31.4K

Top Sellers

Rank Fund Capital Flow
1
BFA
BlackRock Fund Advisors
California
-$74.1K
2
Charles Schwab
Charles Schwab
California
-$9K
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$6.98K
4
FA
FCG Advisors
New Jersey
-$6K
5
DAM
Delta Asset Management
Tennessee
-$4.36K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$9.01M – – –
BIT
2
BlackRock Institutional Trust
California
$1.2M – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$700K -$4.36K -5 -0.8%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$306K +$25.3K +29 +12%
FHA
5
First Horizon Advisors
Tennessee
$100K – – –
D.E. Shaw & Co
6
D.E. Shaw & Co
New York
$99K -$6.98K -8 -8%
Deutsche Bank
7
Deutsche Bank
Germany
$57K +$45.4K +52 New
Renaissance Technologies
8
Renaissance Technologies
New York
$57K +$45.4K +52 New
KLI
9
Kelman-Lazarov Inc
Tennessee
$54.9K +$7.85K +9 +21%
Northern Trust
10
Northern Trust
Illinois
$54K – – –
Jacobs Levy Equity Management
11
Jacobs Levy Equity Management
New Jersey
$49K – – –
Susquehanna International Group
12
Susquehanna International Group
Pennsylvania
$44K +$34.9K +40 New
Citadel Advisors
13
Citadel Advisors
Florida
$43K +$34K +39 New
Stifel Financial
14
Stifel Financial
Missouri
$39K – – –
EWA
15
Exencial Wealth Advisors
Oklahoma
$37K +$31.4K +36 New
Goldman Sachs
16
Goldman Sachs
New York
$36K -$4.36K -5 -13%
Bank of New York Mellon
17
Bank of New York Mellon
New York
$27K -$2.62K -3 -11%
Tudor Investment Corp
18
Tudor Investment Corp
Connecticut
$27K – – –
VKH
19
Virtu KCG Holdings
New York
$26K +$14K +16 +200%
GC
20
Guggenheim Capital
Illinois
$19K +$14.8K +17 New
DAM
21
Delta Asset Management
Tennessee
$18K -$4.36K -5 -24%
Millennium Management
22
Millennium Management
New York
$17K +$14K +16 New
CC
23
Cannell & Co
New York
$16K – – –
State Street
24
State Street
Massachusetts
$16K – – –
DT
25
Diversified Trust
Tennessee
$15K – – –
1
2

ONCT Hedge Fund Activity: Q3 2016 in Review

41 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q3 2016, worth a combined $12.2M — up 45% from $8.41M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new ONCT positions and 2 closed out — a net gain of 7 holders — while 4 added to existing stakes and 10 trimmed.

The largest buyer was Deutsche Bank, opening a new position worth an estimated $45.4K. The largest seller was BlackRock Fund Advisors, cutting an estimated $74.1K.

  • 41 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q3 2016, up from 34 in Q2 2016.
  • Funds reported $12.2M of Oncternal Therapeutics, Inc. Common Stock stock for Q3 2016, up 45% quarter-over-quarter.
  • 9 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q3 2016 and 2 closed out, a net change of +7 holders.
  • The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q3 2016 was Deutsche Bank, an estimated $45.4K added.
  • The largest Oncternal Therapeutics, Inc. Common Stock seller in Q3 2016 was BlackRock Fund Advisors, an estimated $74.1K sold.

Based on aggregated 13F filings for Q3 2016.